Static and Dynamic Assessment of Biomarkers in Surgical Patients with Severe Sepsis
Authors:
- 1 September 2004
- journal article
- research article
- Published by SAGE Publications in Surgical Infections
- Vol. 5 (3) , 261-268
Abstract
Severe sepsis, defined as a systemic inflammatory response to infection associated with acute organ dysfunction, is common among surgical patients and is a major cause of morbidity and mortality. Severe sepsis has been associated with changes in inflammatory and hemostatic biomarkers. In patients undergoing surgical procedures there may be additional stimulation of cytokine release and activation of the coagulation system. The purpose of this study was to characterize the baseline differences in biomarkers between surgical and non-surgical patients. In addition, we assessed the dynamic changes in biomarkers and coagulation parameters in surgical patients with severe sepsis enrolled in PROWESS and treated with placebo or drotrecogin alfa (activated). A blinded PROWESS surgical evaluation committee (SEC) verified patients as having undergone a relevant operative procedure within 30 days of enrollment for inclusion in the surgical cohort of PROWESS. At baseline and on study days 1-7, biomarkers and coagulation parameters available for analysis were D-dimer, interleukin-6 (IL-6), protein C activity, protein S activity, anti-thrombin III (ATIII), activated partial thromboplastin time (aPTT), and prothrombin time (PT). Platelet count was determined at baseline only. Baseline values were compared between SEC-defined surgical and all other non-surgical patients, and between pre- and post-operative surgical patients from the PROWESS trial. Changes from baseline were compared between drotrecogin alfa (activated)-treated and placebo-treated surgical patients. Statistical analyses were performed using ANOVA on the ranked values. The SEC verified 474 (28%) of the 1,690 PROWESS patients as surgical. Median D-dimer, IL-6, aPTT and PT values were significantly higher at baseline for surgical patients than non-surgical patients (p < 0.001). Surgical patients had significantly lower median protein C, protein S, and ATIII activity at baseline than non-surgical patients (p < 0.001). Surgical patients treated with drotrecogin alfa (activated) showed a significant decrease in D-dimer levels on study days 1-5 (p < 0.05), and a more rapid increase in Protein C levels on study days 1-4 (p < 0.05) compared to placebo. Surgical patients with severe sepsis appear to have a higher severity of illness at baseline as demonstrated by derangements in biomarkers and coagulation markers compared to non-surgical patients. Surgical patients treated with drotrecogin alfa (activated)showed reduced D-dimer concentrations and a more rapid increase in protein C concentrations during the infusion period.Keywords
This publication has 19 references indexed in Scilit:
- Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsisThe American Journal of Surgery, 2004
- Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsisThrombosis and Haemostasis, 2003
- Systemic Inflammatory Response Secondary to Abdominal Compartment Syndrome: Stage for Multiple Organ Failure2002
- Major Secondary Surgery in Blunt Trauma Patients and Perioperative Cytokine Liberation: Determination of the Clinical Relevance of Biochemical MarkersThe Journal of Trauma: Injury, Infection, and Critical Care, 2001
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001
- Epidemiology of Multiple Organ Dysfunction Syndrome in Critical Surgical IllnessSurgical Infections, 2000
- Stimulation of the inflammatory system by reamed and unreamed nailing of femoral fracturesThe Journal of Bone and Joint Surgery. British volume, 1999
- Derangements of Coagulation and Fibrinolysis in Critically III Patients with Sepsis and Septic ShockSeminars in Thrombosis and Hemostasis, 1998
- Toward a theory regarding the pathogenesis of the systemic inflammatory response syndromeCritical Care Medicine, 1996
- SERUM LEVELS OF INTERLEUKIN-6 AND ACUTE PHASE RESPONSESThe Lancet, 1987